2026-04-30

press FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, stating there is no clinical need for outsourcing facilities to compound these drugs from bulk substances. The agency is accepting public comments until June 29, 2026, before making a final decision. Read more →